Zalcman G, Mazieres J, Greillier L, et al. Second or 3rd line nivolumab (Nivo) versus nivo plus ipilimumab (Ipi) in malignant pleural mesothelioma (MPM) patients: Updated results of the IFCT-1501 MAPS2 randomized phase 2 trial. ESMO 2017 Congress, abstract LBA58_PR.
Positief BOM-advies voor pembrolizumab bij gemetastaseerd colorectaal carcinoom
feb 2021 | Immuuntherapie, Maag-darm-leveroncologie